XW-014 is under clinical development by Sciwind Biosciences and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XW-014’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XW-014 overview

XW-014 is under development for the treatment of non-alcoholic steatohepatitis (NASH), obesity and  type 2 diabetes. The drug candidate acts by targeting glucagon like peptide 1 (GLP1). It is administered through oral route.

Sciwind Biosciences overview

Sciwind Biosciences is a drug research and development company for metabolic diseases that contain protein and peptide candidates for non-alcoholic steatohepatitis. Sciwind Biosciences is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of XW-014’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.